Tiger Aesthetics' AlloClae uses donor fat for cosmetic procedures

The U.S. company Tiger Aesthetics has marketed AlloClae, a product that injects fat harvested from deceased donors for body‑contouring surgery. Launched in 2024, the treatment is promoted as a ready‑to‑use alternative to autologous fat transfer, with syringes holding up to 22 cm³ of tissue. Company representatives say more than 2,000 patients have been treated since May 2025, and a single 12.5 cm³ syringe can cost about $2,250. Plastic surgeon Luis Macias, based in Los Angeles, notes growing interest among patients, especially after weight‑loss drugs such as Ozempic reduce body volume. AlloClae follows earlier products like Renuva, which used smaller volumes of donor fat. The procedure raises ethical and safety questions, as it relies on tissue from cadavers, prompting debate on consent, sourcing, and regulatory oversight.